| 1  | Ke      | y variants via Alzheimer's Disease Sequencing Project whole genome sequence data  |
|----|---------|---|
| 2  |         |   |
| 3  | Autho   | rs  |
| 4  | Yanbir  | ng Wang,ª Chloé Sarnowski,*ª,b Honghuang Lin,º Achilleas N Pitsillides,ª Nancy L  |
| 5  | Heard   | Costa, <sup>a,d</sup> Seung Hoan Choi, <sup>a</sup> Dongyu Wang, <sup>a</sup> Joshua C Bis, <sup>e</sup> Elizabeth E Blue, <sup>f,g</sup>         |
| 6  | Alzheii | mer's Disease Neuroimaging Initiative (ADNI), Eric Boerwinkle, <sup>b</sup> Philip L De Jager, <sup>h,i</sup>                                     |
| 7  | Myrian  | n Fornage, <sup>b,j</sup> Ellen M Wijsman, <sup>k</sup> Sudha Seshadri, <sup>d,l,m</sup> Josée Dupuis, <sup>a,n</sup> Gina M Peloso, <sup>a</sup> |
| 8  | Anita L | DeStefano <sup>a,d</sup> , for the Alzheimer's Disease Sequencing Project (ADSP)  |
| 9  |         |   |
| 10 | Affilia | tions   |
| 11 | a.      | Department of Biostatistics, Boston University, School of Public Health, Boston, MA,  |
| 12 |         | USA   |
| 13 | b.      | Human Genetics Center, Department of Epidemiology, Human Genetics, and  |
| 14 |         | Environmental Sciences, School of Public Health, The University of Texas Health   |
| 15 |         | Science Center at Houston, Houston, TX, USA   |
| 16 | C.      | Department of Medicine, University of Massachusetts Chan Medical School,  |
| 17 |         | Worcester, MA, USA  |
| 18 | d.      | The Framingham Heart Study, Framingham, MA, USA   |
| 19 | e.      | Cardiovascular Health Research Unit, Department of Medicine, University of  |
| 20 |         | Washington, Seattle, WA, USA  |
| 21 | f.      | Department of Medicine, Division of Medical Genetics, University of Washington,   |
| 22 |         | Seattle, WA, USA  |
| 23 | g.      | Brotman Baty Institute, Seattle, WA, USA  |
| 24 | h.      | Center for Translational & Computational Neuroimmunology, Department of   |
| 25 |         | Neurology, Columbia University Irving Medical Center, New York, NY, USA   |
| 26 | i.      | Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia  |
| 27 |         | University Irving Medical Center, New York, NY, USA   |

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

| 28 | j. Brown Foundation Institute of Molecular Medicine, McGovern Medical School,            |           |
|----|--|-----------|
| 29 | University of Texas Health Science Center at Houston, Houston, TX, USA                   |           |
| 30 | k. Div. of Medical Genetics and Dept. Biostatistics Statistical Genetics Lab, University | ersity of |
| 31 | Washington, Seattle, WA, USA   |           |
| 32 | I. Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, The Univ          | versity   |
| 33 | of Texas Health Science Center at San Antonio, San Antonio, TX, USA                      |           |
| 34 | m. Boston University School of Medicine, Department of Neurology, Boston, MA,            | USA       |
| 35 | n. Department of Epidemiology, Biostatistics and Occupational Health, School of          | :         |
| 36 | Population and Global Health, McGill University, Montreal, Canada                        |           |
| 37 |  |           |
| 38 | Corresponding authors  |           |
| 39 | Dr. Chloé Sarnowski, email: Chloe.Sarnowski@uth.tmc.edu (editorial office correspor      | ndence)   |
| 40 | Dr. Anita L Destefano, email: adestef@bu.edu   |           |
| 41 |  |           |
| 42 | Drs. Yanbing Wang and Chloé Sarnowski contributed equally to this work. Drs. Gina I      | Peloso    |
| 43 | and Anita L DeStefano contributed equally to the supervision of this work.               |           |
| 44 |  |           |
| 45 | Abbreviations: Alzheimer's disease (AD), the Alzheimer's Disease Sequencing              | Project   |
| 46 | (ADSP), Black/African-American (AA), Combined Multivariate and Collapsing                | (CMC),    |
| 47 | White/European-ancestry (EA), Genome-Wide Association Studies (GWAS),                    | Genetic   |
| 48 | Relationship Matrix (GRM), Hispanic/Latino (HI), Linkage Disequilibrium (LD), Mino       | or Allele |
| 49 | Count (MAC), Minor Allele Frequency (MAF), Mild Cognitive Impairment (MCI), F            | Principal |
| 50 | Component Analysis (PCA), Quality Control (QC), Sequence Kernel Association Test         | (SKAT),   |
| 51 | variant-Set Test for Association using Annotation infoRmation (STAAR), Whole G           | Genome    |
| 52 | Sequencing (WGS)   |           |
| 53 |  |           |
|    |  |           |

2

## 56 Abstract

- INTRODUCTION: Genome-wide association studies (GWAS) have identified loci associated
  with Alzheimer's disease (AD) but did not identify specific causal genes or variants within those
  loci. Analysis of whole genome sequence (WGS) data, which interrogates the entire genome
  and captures rare variations, may identify causal variants within GWAS loci.
- 61 METHODS: We performed single common variant association analysis and rare variant
- 62 aggregate analyses in the pooled population (N cases=2,184, N controls=2,383) and targeted
- analyses in sub-populations using WGS data from the Alzheimer's Disease Sequencing
- 64 Project (ADSP). The analyses were restricted to variants within 100 kb of 83 previously
- 65 identified GWAS lead variants.
- 66 RESULTS: Seventeen variants were significantly associated with AD within five genomic
- 67 regions implicating the genes OARD1/NFYA/TREML1, JAZF1, FERMT2, and SLC24A4.
- 68 KAT8 was implicated by both single variant and rare variant aggregate analyses.
- DISCUSSION: This study demonstrates the utility of leveraging WGS to gain insights into ADloci identified via GWAS.
- 71
- Keywords: Alzheimer's disease; Whole Genome Sequencing; Association Analyses; Single
   Nucleotide Variations; Diverse Populations; Genome Wide Association Study
- 74
- 75
- . .
- 76
- 77
- ,,
- 78
- 79
- 80
- 81
- 82
- 83

#### 84 **1. Introduction**

85 Alzheimer's disease (AD), the most common cause of dementia, has been ranked as the 6th leading cause of death in the United States and the 5th leading cause of death in older people 86 87 (≥65 years old). Although the role of genetic factors in the development of AD has been widely 88 recognized, genome-wide association studies (GWAS) typically identify regions or loci rather 89 than specific genes and/or variants. Additionally, the loci identified by GWAS only explain a 90 small portion of the total heritability of AD ( $h^{2}_{AD} = [0.58 - 0.79]$ ).<sup>1</sup> Next-generation sequencing 91 technology applied in diverse populations as part of the Alzheimer's Disease Sequencing 92 Project (ADSP) may help to elucidate the genetic architecture of AD, and thus, aid in the 93 development of effective strategies to diagnose, prevent and treat AD.<sup>2</sup>

94 A recent large GWAS totalling 111,326 clinically diagnosed/proxy' AD cases and 677,663 95 controls has identified over 70 loci associated with AD and related dementias.<sup>3</sup> However, the 96 characterization of these loci remains incomplete. Leveraging whole genome sequence 97 (WGS) data that encompasses the full spectrum of genetic variation including common and 98 rare variants might identify important AD genes within these GWAS loci and provide a better 99 understanding of the biological mechanisms involved in the pathophysiology of AD. Previous 100 studies used WGS to identify genetic loci associated with AD.<sup>3-6</sup> A family-based study 101 conducted in 2,247 subjects from NIMH/NIA with replication in 1,669 independent participants 102 from the ADNI/ADSP identified 13 novel AD candidate loci with rare-variant signals (FNBP1L, 103 SEL1L, LINC00298, PRKCH, C15ORF41, C2CD3, KIF2A, APC, LHX9, NALCN, CTNNA2, SYTL3, and CLSTN2).<sup>3</sup> More recently, the same team investigated association of groups of 104 rare variants in the same datasets using a sliding-window approach and identified two novel 105 genes (DTNB and DLG2) associated with AD.<sup>4</sup> Additional studies conducted in Asian 106 107 populations highlighted the importance of increasing representation of understudied population groups and value of WGS to uncover population-specific genetic loci.<sup>5,6</sup> 108

In this work, we focused on deep interrogation of known AD GWAS loci<sup>7</sup> using the ADSP WGS
data. The ADSP aims to identify protective or risk genetic contributors for AD in populations
with diverse ancestry. The ADSP has generated single nucleotide variant and

insertion/deletion (indel) calls based on WGS data from 4,789 participants, which are publicly available (R1 data release https://dss.niagads.org/datasets/ng00067-v1/). The goal of the current study is not replication of prior GWAS findings as we are underpowered to do so. In addition, the ADSP sample in the current analyses is not independent of the sample used in Bellenguez et al.<sup>7</sup> Instead we aim to provide a more comprehensive look at GWAS loci.

117 We conducted single variant association analyses and rare variant aggregation association 118 tests using the R1 WGS data of ADSP to identify specific genetic variants, genes and non-119 coding regions associated with AD within previously identified AD loci. We also examined 120 multi-ancestry evidence for AD associations through population-specific analyses in 121 White/European-ancestry (EA), Black/African-American (AA) and Hispanic/Latino (HI) 122 subgroups, and a multi-population meta-analysis. The insights gained from our analysis will 123 contribute to a better understanding of the AD pathogenesis and to potentially identify new 124 targets for AD drug and treatment.

125

#### 126 **2. Methods**

#### 127 2.1 Study Participants

128 Data from the ADSP is available to qualified investigators via the National Institute on Aging 129 Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) (https://dss.niagads.org/). 130 This study was done under an approved NIAGADS research use statement and local 131 Institutional Review Board approval. The current analyses focused on participants with WGS data in the NIAGADS file set named "R1 5K WGS Project Level VCF". WGS data have been 132 generated in multiple cohorts as part of the ADSP. The ADSP data included in this study are 133 comprised of distinct phases including the Discovery, Discovery Extension, and Augmentation 134 135 phases. The Discovery phase WGS was generated from individuals of multiplex AD families as previously described.<sup>8-10</sup> The Discovery Extension phase consisted of a family component 136 and a case control component. The Discovery Extension family component WGS was 137 generated on additional members of selected families from the Discovery phase as well as 138

members of 77 additional families. A set of 114 Hispanic control individuals was alsosequenced with the family component.

141 A focus of the Discovery Extension case control component was to increase the diversity of the ADSP samples. The ADSP Discovery Extension WGS was generated on 3,082 142 143 individuals, with approximately one third from EA, AA, and HI populations. In the ADSP 144 Discovery and Discovery Extension phases sequencing was performed at three sequencing 145 centers via the National Human Genome Research Institute (NHGRI). Sequence data for 146 ADSP Augmentation Studies were supported by NIA and private funding and are shared with 147 the research community via NIAGADS. The ADSP data coordinating center, the Genomic 148 Center for AD (GCAD), produced a jointly called and quality controlled (QC'ed) data set for WGS10 that included the ADSP WGS Discovery, Discovery Extension, and from the 149 150 Augmentation phase, the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. Details 151 of studies included in the ADSP can be found at NIAGADS under dataset: NG00067 ADSP 152 Umbrella Study (https://dss.niagads.org/datasets/ng00067/).

153

#### 154 2.2 WGS Quality Control

155 Low-quality variants were filtered out based on the GCAD provided flags, which were 156 generated separately for the Family, Case-Control, and ADNI sub-studies.<sup>10</sup> In addition, GCAD 157 provided the ABHet ratio computed as (the total reference reads over all heterozygous genotypes)/(total alternative and reference reads over all heterozygous genotypes). A variant 158 159 was excluded if it failed the GATK Variant Quality Score Recalibration (VQSR) filter, all 160 genotypes were missing, was monomorphic, or if it had low call rate across all studies. 161 Additional filtering was implemented within sub-study. If a variant had high read depth (>500 reads) within a study or had ABHet < 0.25 or ABHet > 0.75 within a sub-study, all the 162 genotypes within that sub-study were set to missing. After these filters were applied, a final 163 164 call rate filter of 95% across all sub-studies was implemented.

165

#### 166 2.3 AD Phenotype Definition

167 The ADSP provides different AD status variable definitions for participants included via case-168 control versus family-based studies. In the current analysis, for individuals in the ADSP case-169 control study, we defined AD cases as individuals with either prevalent or incident AD. Case-170 control individuals with no prevalent or incident AD were defined as controls and those with 171 missing status were defined as unknown. In the ADSP family phenotype file, possible values 172 for the AD status variable include no dementia, definite AD, probable AD, possible AD, family-173 reported AD, other dementia, family reported no dementia, and unknown. For family-based 174 individuals, we defined an AD case as either possible, probable or definite AD. AD controls 175 were defined as individuals coded as no dementia. We redefined individuals with family-176 reported AD, other dementia, or unknown status as missing AD status. The ADNI phenotype 177 data, which is part of the ADSP Augmentation study, provides information on mild cognitive 178 impairment (MCI) in addition to AD status. Individuals with a current diagnosis of MCI (N=320) 179 were included as AD controls in the current study. After selecting genetically unique individuals 180 with AD status available, a total of 4,567 participants (2,383 controls and 2,184 cases) with 181 WGS were included in the analyses.

182

183 2.4 Pooled sample single-variant association analysis

Single-variant association analysis of AD was performed on variants within GWAS loci for 184 185 participants with both phenotype and genotype data available using GENESIS.<sup>11</sup> Principal component analysis (PCA) was performed as described in the supplemental methods to 186 187 assess and adjust for genetic ancestry of the study participants (Figure A1). The WGS 188 samples included in the ADSP R1 WGS data set were sequenced across four sequencing 189 centers (Baylor College of Medicine Human Genome Sequencing Center, The Broad Institute, 190 McDonnell Genome Institute at Washington University School of Medicine, and Illumina) and 191 2 sequencing platforms (Illumina HiSeq 2000/2500, and Illumina HiSeq X Ten). In order to 192 control for the effects from study design and technical differences, we generated indicator 193 variables (study×sequencing center×sequencing platform) with 10 categories based on Table 194 1. We considered these indicator variables as technical covariates and defined case-control x

Broad x HiSeq X Ten, which had the largest number of observations, as the reference group. We used a generalized logistic mixed-effects model to account for relatedness through a genetic relationship matrix (GRM). The GRM was estimated based on the same variants used in the PCA. We included sex, the technical covariates, and PC2 (based on a Bonferroni corrected significant p < 0.0016 for testing 32 PCs) as covariates in the null model. We performed the analysis across autosomes, and kept variants satisfying the criteria: call rate higher than 95% and minor allele count (MAC) higher than 20.

To determine if significant variants identified provided distinct signals from the lead GWAS variants,<sup>7</sup> conditional analyses were performed in loci displaying significant associations. Genotype data, coded as 0/1/2, for the lead GWAS variants in these loci was included in the null model in addition to the covariates. Association analyses conditioned on the lead GWAS variants were then rerun for the loci of interest.

207

208 2.5 Population specific association analysis

209 We conducted population specific analyses (null model and association analyses) for AD using 210 GENESIS, accounting for genetic relatedness using a GRM. We defined three population 211 groups (EA, AA, and HI). We selected a total of 2,144 EA participants based on PCA analysis 212 performed using both the ADSP and the Human Genome Diversity Project (HGDP). Only 213 participants who were not outliers based on 6 standard deviations (SD) from the mean for PCs 214 1-4 calculated in the European HGDP groups (Adygei, Basque, French, Bergamoltalian, Orcadian, Russian, Sardinian, and Tuscan) were retained. We selected a total of 1,028 AA 215 216 and 1,548 HI participants based on reported race and ethnicity. A total of 38 participants who 217 identified as both African-American and Hispanic were placed in the Hispanic population. We 218 included in the null model, in each population group, covariates associated with AD status at  $P \le 0.05$ . The EA null model included sex, ADSP family study status, Illumina sequencing 219 center, HiSeq X Ten platform, PC 2, PC 9, and PC 15. The HI null model included sex, all 220 sequencing centers, HiSeq X Ten platform, PC 13, PC 16, and PC 17. The AA null model 221 222 included sex, Illumina sequencing center, and PC 1. We performed association analyses, in

each population group, and retained the results with call rate higher than 95% and minor allele
count (MAC) higher than 20. In addition, we performed a multi-population meta-analysis using
three different models (fixed-effect, random-effect, and Han & Eskin's modified random-effect)
implemented in Metasoft<sup>12</sup> by combining the population specific results satisfying the criteria
of a within population MAC higher than 10. We then kept the meta-analysis results passing a
total MAC across population groups higher than 20.

229

230 2.6 Gene-based tests

231 We tested the association of aggregate groups of low frequency (minor allele frequency (MAF) 232 < 5%) or rare (MAF < 1%) genetic variants with AD status. Annotation for all called variants 233 was generated using Ensembl VEP91 by the ADSP annotation working group. We selected 234 missense or loss of function (lof) genetic variants based on the most severe variant 235 consequence according to the ADSP Annotation WG Ranking Process and listed in the 236 annotation file (frameshift variant, inframe deletion, inframe insertion, missense variant, 237 protein-altering variant, splice acceptor variant, splice donor variant, start lost, stop gained, 238 and stop lost). We conducted Sequence Kernel Association Test (SKAT, mmskat) and burden 239 tests (combined multivariate and collapsing (CMC), emmaxCMC) with EPACTS (Efficient and 240 Parallelizable Association Container Toolbox) using mixed-effect models adjusted for sex, 241 technical covariates, and PCs significantly associated with AD status (PC2) accounting for genetic relatedness (GRM). 242

243

244 2.7 Non-coding rare variant analysis

For non-coding rare variant analysis, we used annotations from WGSA v0.8<sup>13</sup> including annotations from ANNOVAR, VEP, SnpEff, COSMIC and SPIDEX. We conducted rare variant analysis using the variant-Set Test for Association using Annotation infoRmation (STAAR) method,<sup>14</sup> which was developed to boost power of rare variant analyses by effectively incorporating both variant functional categories and multiple complementary functional annotations while accounting for relatedness and population structures. We used the same

covariates (sex, technical covariates, and significant PCs) in the model as in single-variant
 analysis. The GRM was incorporated to account for relatedness among samples.

253 We aggregated sites that overlap enhancers and promoters around gene transcription start 254 sites (TSS). The promoters within 5KB of a TSS that overlap DNase hypersensitivity sites 255 (DHS) are defined as at least one WGSA H3K4me3 annotation for brain tissues (E067, E068, 256 E069, E070, E071, E072, E073, E074, E081, E082), and the enhancers within 20KB of a TSS 257 are defined by EnhancerFinder in Brain. We incorporated annotations from WGSA in the 258 analysis, which include MAF, functional scores (GERP, GenoCanyon, RegulomeDB, FUNSEQ, CADD, Fathmm, EIGEN-PC), and the ENCODE score (DNASE). We then 259 260 transformed the annotation scores to phred-scaled scores using -10×log10(rank(-score)/M), 261 where M is the total number of variants tested in the analysis.

262

263 2.8 Focus on GWAS loci

264 Given the limited power to detect novel loci with the current sample size, we focused on 265 exploiting WGS to provide insights on previously reported AD GWAS loci. We used the 266 variants listed in Supplemental Table 5 in Bellenguez et. al as the previously reported AD 267 GWAS top variants. For single variant association analyses, we looked up these lead variants 268 in the ADSP WGS data. We then assessed ADSP WGS associations within 100KB of each 269 lead GWAS variant. For gene-based and non-coding rare variant analysis, we obtained the 270 results for genes or regions in the 100KB window around each lead variant. We included genes or non-coding regions for which any portion overlapped with the specified window. 271 272 Using this paradigm, we identified 303 genes within 100kb of the index SNPs.

In general, we defined a threshold for statistical significance equal to 0.05/number of statistical tests and a suggestive threshold as 1/number of statistical tests. Within a 100kb window, many single variant tests were highly correlated. Therefore, we computed the effective number of independent tests using the simpleM approach<sup>15</sup> and used the effective number of tests in the denominator when computing a window-specific threshold for single variant association

testing. Effective number of tests were computed across the pooled sample and within each
population sub-group (Table A1). Figure 1 provides an overview of our analysis workflow.
We leveraged publicly-available multi-omic resource generated by applying quantitative trait
locus (xQTL) analyses to RNA sequence and DNA methylation from the dorsolateral prefrontal
cortex of 411 older adults from the Religious Orders Study (ROS) and Memory and Aging
Project (MAP) studies<sup>16</sup> to look-up the main genetic variants from the pooled association
analysis.

- 285
- 286 **3. Results**
- 287 3.1 Description of ADSP data

After the QC of the ADSP data release NG00067.v2, there were over 95 million variants across 4,733 participants. A total of 4,567 individuals (2,383 controls, 2,184 cases) have available AD status and contributed to the analyses, among which 807 are from the ADSP family study, 2,963 are from the ADSP case-control study, and 797 are from ADNI. The participants included in the analyses were more likely to be women (61.8%) than men. The distribution of study design membership, sequencing centers, and sequencing platforms is summarized in **Table 1**.

295

296 3.2 Pooled sample single-variant association analysis

Genome-wide, there were about 20 million variants with call rate higher than 95% and MAC higher than 20 in the pooled sample analysis. Our model that included GRM and PC adjustments showed acceptable type-I error control ( $\lambda = 1.05$ , **Figure A2**). As expected, the strongest association was observed at the *APOE* locus, where the major *APOE* variant rs429358 (p = 7.2 × 10<sup>-77</sup>) was the top hit.

Among the specific lead GWAS variants from Bellenguez et al,<sup>7</sup> none reached the strict significance threshold (p < 6 × 10<sup>-4</sup>, Bonferroni correction for the total number of variants tested) in the pooled sample association analysis. Using the suggestive significance threshold (p < 0.012; 1/83), we found associations for rs7401792 (p =  $7.3 \times 10^{-4}$ , MAF= 49.2%) in the

306 *SLC24A4* locus, rs75932628 (p =  $3 \times 10^{-3}$ , MAF= 0.35%) in the *TREM2* locus, rs616338 (p= 307 4.4 × 10-3, MAF= 0.71%) in the *ABI3* locus, rs1358782 (p =  $4.9 \times 10^{-3}$ , MAF= 22.9%) in the 308 *RBCK1* locus, rs1160871 (p =  $6.9 \times 10^{-3}$ , MAF= 40.2%) in the *JAZF1* locus, and rs602602 (p 309 = 0.12, MAF= 27.7%) in the *MINDY2* locus. Full results for the 83 lead GWAS variants are 310 provided in the supplement (**Table A2**).

311 Applying the significance thresholds based on the effective number of tests within 100 kb 312 windows around the lead GWAS variants (Table A1), we identified 17 significant variants in 313 the single variant association analysis in the pooled sample (**Table 2**). These 17 variants occur 314 in five genomic regions on chromosomes 6, 7, 14, and 16. Forest plots for the top variant in 315 each of these five regions are presented in Figure 2. Examination of linkage disequilibrium 316 (LD) patterns show near perfect LD among the variants identified on chromosome 6, on 317 chromosome 7 or for the one region on chromosome 14 with multiple variants. Only a single 318 variant was identified on chromosome 16 and in one region on chromosome 14. Detailed LD 319 information is provided in the supplement (Figure A3).

Conditional analyses were performed to determine if these associations represented the same
signal as the lead GWAS variant from Bellenguez et al or a distinct signal. As shown in **Table 2**, the inclusion of the lead GWAS variant in the association model did not mitigate the
association indicating the variants identified represent a distinct signal from the lead GWAS
variants.

325

3.3 Population specific single-variant association analysis and multi-population meta-analysis 326 327 We conducted population specific association analyses in the three main subgroups (N=2,043 328 EA; N=995 AA, and N=1,516 HI participants). There was acceptable type-I error in the 329 population specific analyses and the multi-population meta-analysis (Figures A4-A7). We confirmed the significant association of the APOE locus (rs429358) in both the population 330 331 specific analyses and the multi-population meta-analysis. However, as found in previous 332 studies<sup>17,18</sup> the association was weaker in the Hispanic population (beta = 1.17 in EA, 1.02 in 333 AA, and 0.59 in HI).

Population specific single variant analyses identified 23 significant variants in 11 loci within 100 kb of the lead GWAS variants (**Table 3**). Of these, 15 variants (8 loci) were identified in the EA population and 8 variants (3 loci) in the AA population. No significant variants were identified in the HI population. The only overlap in significant variants between the pooled sample and the population specific single-variant analyses was a missense variant in *KAT8*, which was very rare in the AA and HI subsamples (**Table A3**).

340

#### 341 3.4 Gene-based tests

QQ plots for the SKAT and burden tests are provided in **Figure A8**. Using the multiple-testing correction threshold for 303 genes (p <  $1.7 \times 10^{-4}$ ), *KAT8* (p =  $2.2 \times 10^{-5}$ , MAF< 5%) lying within 100 KB of a GWAS variant was detected to be significantly associated with AD status by SKAT, and it was also shown as a suggestive association (p <  $3.4 \times 10^{-3}$ ) using CMC (p =  $9.2 \times 10^{-4}$ ). SKAT detected suggestive associations in *LAIR1* (p = 0.0023, MAF < 5%) and *ATF5* (p =  $5.7 \times 10^{-4}$ , MAF < 5%) within 100KB. CMC identified *TREM2* (p =  $3.3 \times 10^{-3}$  for MAF < 1% and 8.9 x 10<sup>-4</sup> for MAF < 5%) within 100KB of GWAS variants.

349

350 3.5 Non-coding rare variant analysis

351 QQ plots showed deflated type-I error ( $\lambda = 0.75$ ), most likely due to small sample size, in the 352 STAAR rare-variant analysis. (**Figure A9**). No regions were identified as significant using the 353 STAAR approach. The top STAAR results overlapping GWAS loci are shown in **Table A3**.

354

355 3.6 xQTL analysis lookup

We did not identify significant mQTL or eQTL associations for the main genetic variants identified in the pooled analysis. We could not look up some of the less frequent variants on chr7, 14 and 16 in the QTL results as these analyses were restricted to common variants. Suggestive associations have been reported between rs10947950 (chr6) and cg25473438 (beta = 0.24, P =  $1.4 \times 10^{-8}$ ) and between rs7155002 (chr14) and cg12072028 (beta = 0.19, P =  $5.8 \times 10^{-6}$ ), **Table A4**. The CpG cg12072028 is located in the intron 1 of *RIN3* and modest

associations have been described between rs7155002 and *RIN3* expression in the brain (beta
= 0.04, P = 0.01), **Table A4**.

364

## 365 Discussion

366 GWAS have been essential in identifying genetic loci associated with AD. However, GWAS 367 loci typically contain scores of genes and thousands of variants. Additional studies are needed 368 to pinpoint specific genes or variants as the ones influencing risk for AD. WGS provides 369 complete genomic sequence and hence enumerates both common and rare variants. WGS 370 therefore has the potential to provide information beyond common variants that are the 371 cornerstone of GWAS. In the current study, we have examined WGS from the ADSP R1 data 372 set focusing on previously implicated regions to better understand important variants within 373 AD GWAS loci in a diverse study sample. We identified 17 significant variants in five genomic 374 regions using single variant association analysis in the pooled sample. The majority of these 375 variants were intronic, although two intergenic and one missense variant were also identified. 376 Bellenguez et al<sup>7</sup> identified multiple lead GWAS variants on chromosome 6, which yielded 377 overlapping 100kb windows defined by our approach. We identified seven significant variants 378 on chromosome 6 that are in nearly complete LD. Six of these variants are located within 379 intronic regions of OARD1 and NFYA genes, and one variant is very close to APOBEC2. One 380 variant was intergenic with the closest gene being TREML1. This region contains TREM2, for which several rare coding variants have been implicated as conferring risk for AD.<sup>19-22</sup> TREM2 381 382 showed suggestive evidence of association in gene-based analyses indicating multiple 383 variants in this region are likely to play an important role in AD. The missense variant 384 rs75932628 was one of the lead GWAS variants from Bellenguez et al. and has been identified 385 as a functional variant for AD.<sup>23-25</sup> The variant rs75932628 has an MAF=0.0035 in the ADSP 386 pooled sample and p=0.003 for single variant association with AD. This suggestive association 387 is driven by the EA population (MAF=0.007) as this variant is less frequently observed in the 388 AA (MAF=0.001) or HI (MAF=0.0003) populations. Our conditional analysis indicates that the 389 variants we identified implicating OARD1/NFYA/TREML1 have a distinct effect from

390 rs75932628. OARD1 encodes a deacylase with a function to catalyse O-acetyl-ADP-ribose during multiple cellular processes. A homozygous mutation could lead to cell death and cause 391 a form of childhood neurodegenerative disorder.<sup>26</sup> NFYA encodes a subunit of nuclear 392 transcription factor Y, which is a ubiquitous transcription factor. The gene is involved in post-393 394 transcriptional regulation with tissue-specific preference, and it is suppressed in the brain of model mice with Huntington's disease<sup>27</sup> and spinal and bulbar muscular atrophy.<sup>28</sup> TREML1 395 396 encodes a protein belonging to the family of triggering receptors expressed on myeloid cells-397 like (TREM). A deficiency of TREML1 might result in haemorrhage due to localized inflammatory lesions.29 398

The five significant variants on chromosome 7 are in a strong LD block and all variants are intronic for *JAZF1*, which encodes a transcriptional repressor. The gene has been linked with diabetes mellitus and cancer, but also has a role in lipid metabolism supporting the connection between lipid levels and AD.<sup>30</sup> The *JAZF1* GWAS variant (rs1160871) is a strong eQTL in microglia and considered a Tier 1 (highly plausible) AD gene.<sup>7</sup> The significance of the variants at this locus was slightly attenuated by conditioning on the nearby GWAS variant (rs1160871), indicating that this may be a shared effect with the lead GWAS variant.

406 We identified two regions on chromosome 14, with significant variants intronic to FERMT2 and 407 SLC24A4. The association of the intronic variant rs7155002 for SLC24A4 was slightly 408 attenuated by the conditional analysis indicating that this may be a shared effect with the lead 409 GWAS variant. Lookup in brain xQTL data shed light on potential biological regulatory mechanisms in *RIN3* that has also been implicated in AD.<sup>31,32</sup> *FERMT2* encodes plekstrin 410 homology domain-containing family C member 1 and is known to be involved in APP 411 metabolism.<sup>33</sup> The under-expression of *FERMT*2 was associated with mature APP level 412 increment in the cell surface.<sup>33</sup> Previous studies reported that *FERMT2* is also involved in 413 cardiac and skeletal muscle development<sup>34</sup> and cancer progression.<sup>35,36</sup> SLC24A4 encodes a 414 member of the potassium-dependent sodium/calcium exchanger protein family and is 415 associated with neural development.<sup>37</sup> A homozygous mutation in SLC24A4 may cause 416 amelogenesis imperfecta<sup>38,39</sup> but the function of *SLC24A4* in AD is not clear vet. 417

418 A rare missense variant (rs201871085, MAF = 0.0108 in the pooled sample) within KAT8 (lysine acetyltransferase 8) on chromosome 16 was significantly associated with AD. KAT8 419 420 was also significant in the low-frequency variant gene-based analyses. KAT8 encodes a 421 member of the MYST histone acetylase protein family that has a characteristic MYST domain 422 containing an acetyl-CoA-binding site, a chromodomain typical of proteins which bind 423 histones, and a C2HC-type zinc finger. This gene has been recently identified by two largescale GWAS of clinically diagnosed AD and family history of AD<sup>40,41</sup> and by a novel knockoff 424 425 method when applied to the ADSP Data.<sup>42</sup> Aberrant expression patterns of KAT8 might be associated with AD progression.<sup>43</sup> KAT8 appears like a promising candidate gene that is 426 involved in cerebral development<sup>44</sup> and may play a role in neurodegeneration in both AD and 427 428 Parkinson's disease.<sup>45,46</sup> We were not able to look-up the variant rs201871085 in the brain 429 xQTL data. This variant might not have been analyzed due to a low frequency or a low quality 430 of imputation, thus highlighting the importance of leveraging whole genome sequence data.

431 The ADSP represents a diverse population sample, although in this early release of ADSP 432 WGS data the sample size within a specific population is limited ( $N_{EA} = 2.043$ ,  $N_{AA} = 995$ ,  $N_{HI}$ 433 = 1,516). Population specific analyses provide information about patterns of allele frequency 434 for AD associated variants among populations. Among the five loci identified as significant in 435 the pooled single variant association analysis, two regions (chr6 & 16) displayed EA-specific 436 associations and corresponded to low frequency variants in EA that were rare in other population groups. One signal (chr7) was driven by a variant common in AA with a low 437 frequency in HI, and rare in EA. Finally, two regions (chr14) were driven by HI signals with one 438 439 variant common in all population groups, and one variant common in HI but rare in EA and 440 AA. All these results are summarized in **Table A3**.

The signals identified only in AA in the population specific analyses (chr4 and 14) corresponded to SNPs common in AA that were less common in HI and rare in EA. A few signals identified only in EA corresponded to variants that were rare in all population groups (chr8, 17 and 20). Two low frequency signals identified only in EA (chr16 and 17) corresponded to SNPs that were rare in AA and HI. Finally, three signals identified only in EA

446 (chr5, 14, and 16) corresponded to SNPs that were common in different population groups.

447 All these results are summarized in **Table 3**.

A strength of this study is the analysis of WGS data that was jointly called and QC'ed by a single data coordinating center. The diversity in genetic ancestry of the participants included is another strength. Despite this diversity, a limitation of the study is the moderate sample size within each population analysed. To overcome this limitation, main analyses were focused on the pooled sample. The ADSP is ongoing with larger WGS data sets being publicly released and planned. Future analyses with larger sample size may yield additional insights, specifically for population specific effects. The current study demonstrates the importance of leveraging whole genome sequence data to gain insights into loci identified via GWAS and highlights the contribution of low frequency variants to AD risk.

#### 474 **References**

- 475 1. Karlsson IK, Escott-Price V, Gatz M, et al. Measuring heritable contributions to
- 476 alzheimer's disease: Polygenic risk score analysis with twins. *Brain Commun.*
- 477 2022;4(1):fcab308. doi: 10.1093/braincomms/fcab308.
- 478 2. Beecham GW, Bis JC, Martin ER, et al. The alzheimer's disease sequencing project:
- 479 Study design and sample selection. *Neurol Genet.* 2017;3(5):e194. doi:
- 480 10.1212/NXG.00000000000194.
- 481 3. Prokopenko D, Morgan SL, Mullin K, et al. Whole-genome sequencing reveals new
- 482 alzheimer's disease-associated rare variants in loci related to synaptic function and neuronal
- 483 development. *Alzheimers Dement*. 2021;17(9):1509-1527. doi: 10.1002/alz.12319.
- 484 4. Prokopenko D, Lee S, Hecker J, et al. Region-based analysis of rare genomic variants in
- 485 whole-genome sequencing datasets reveal two novel alzheimer's disease-associated genes:
- 486 DTNB and DLG2. *Mol Psychiatry*. 2022;27(4):1963-1969. doi: 10.1038/s41380-022-01475-0.
- 487 5. Shigemizu D, Asanomi Y, Akiyama S, Mitsumori R, Niida S, Ozaki K. Whole-genome
- 488 sequencing reveals novel ethnicity-specific rare variants associated with alzheimer's
- disease. *Mol Psychiatry*. 2022;27(5):2554-2562. doi: 10.1038/s41380-022-01483-0.
- 490 6. Park J, Park I, Youm EM, et al. Novel alzheimer's disease risk variants identified based on
- 491 whole-genome sequencing of APOE epsilon4 carriers. *Transl Psychiatry*. 2021;11(1):296-9.
- 492 doi: 10.1038/s41398-021-01412-9.
- 493 7. Bellenguez C, Kucukali F, Jansen IE, et al. New insights into the genetic etiology of
- 494 alzheimer's disease and related dementias. *Nat Genet*. 2022;54(4):412-436. doi:
- 495 10.1038/s41588-022-01024-z.
- 496 8. Tsapanou A, Scarmeas N, Gu Y, et al. Data from a cross-sectional study on
- 497 apolipoprotein E (APOE-epsilon4) and snoring/sleep apnea in non-demented older adults.
- 498 Data Brief. 2015;5:351-353. doi: 10.1016/j.dib.2015.09.014.
- 499 9. Chung J, Zhang X, Allen M, et al. Genome-wide pleiotropy analysis of neuropathological
- 500 traits related to alzheimer's disease. *Alzheimers Res Ther.* 2018;10(1):22-z. doi:
- 501 10.1186/s13195-018-0349-z.

- 502 10. Naj AC, Lin H, Vardarajan BN, et al. Quality control and integration of genotypes from
- 503 two calling pipelines for whole genome sequence data in the alzheimer's disease
- 504 sequencing project. *Genomics*. 2019;111(4):808-818. doi: 10.1016/j.ygeno.2018.05.004.
- 505 11. Gogarten SM, Sofer T, Chen H, et al. Genetic association testing using the GENESIS
- 506 R/bioconductor package. *Bioinformatics*. 2019;35(24):5346-5348. doi:
- 507 10.1093/bioinformatics/btz567.
- 508 12. Han B, Eskin E. Random-effects model aimed at discovering associations in meta-
- analysis of genome-wide association studies. *Am J Hum Genet*. 2011;88(5):586-598. doi:
- 510 10.1016/j.ajhg.2011.04.014.
- 511 13. Liu X, White S, Peng B, et al. WGSA: An annotation pipeline for human genome
- 512 sequencing studies. J Med Genet. 2016;53(2):111-112. doi: 10.1136/jmedgenet-2015-
- 513 103423.
- 14. Li X, Li Z, Zhou H, et al. Dynamic incorporation of multiple in silico functional annotations
- 515 empowers rare variant association analysis of large whole-genome sequencing studies at
- 516 scale. Nat Genet. 2020;52(9):969-983. doi: 10.1038/s41588-020-0676-4.
- 517 15. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic
- 518 association studies using correlated single nucleotide polymorphisms. *Genet Epidemiol*.
- 519 2008;32(4):361-369. doi: 10.1002/gepi.20310.
- 520 16. Ng B, White CC, Klein H, et al. An xQTL map integrates the genetic architecture of the
- 521 human brain's transcriptome and epigenome. Nat Neurosci. 2017;20(10):1418-1426. doi:
- 522 10.1038/nn.4632.
- 523 17. Blue EE, Horimoto ARVR, Mukherjee S, Wijsman EM, Thornton TA. Local ancestry at
- 524 APOE modifies alzheimer's disease risk in caribbean hispanics. Alzheimers Dement.
- 525 2019;15(12):1524-1532. doi: 10.1016/j.jalz.2019.07.016.
- 526 18. Campos M, Edland SD, Peavy GM. Exploratory study of apolipoprotein E epsilon4
- 527 genotype and risk of alzheimer's disease in mexican hispanics. J Am Geriatr Soc.
- 528 2013;61(6):1038-1040. doi: 10.1111/jgs.12292.

- 529 19. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk
- 530 of alzheimer's disease. *N Engl J Med*. 2013;368(2):107-116. doi: 10.1056/NEJMoa1211103.
- 531 20. Li R, Wang X, He P. The most prevalent rare coding variants of TREM2 conferring risk of
- alzheimer's disease: A systematic review and meta-analysis. *Exp Ther Med.* 2021;21(4):347.
- 533 doi: 10.3892/etm.2021.9778.
- 534 21. Jin SC, Benitez BA, Karch CM, et al. Coding variants in TREM2 increase risk for
- 535 alzheimer's disease. *Hum Mol Genet*. 2014;23(21):5838-5846. doi: 10.1093/hmg/ddu277.
- 536 22. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in alzheimer's disease. *N Engl J*
- 537 *Med.* 2013;368(2):117-127. doi: 10.1056/NEJMoa1211851.
- 538 23. Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M. Humanized TREM2
- 539 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. *J Exp Med*.
- 540 2018;215(3):745-760. doi: 10.1084/jem.20171529.
- 541 24. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in alzheimer's disease. N Engl J
- 542 *Med.* 2013;368(2):117-127. doi: 10.1056/NEJMoa1211851.
- 543 25. Xiang X, Piers TM, Wefers B, et al. The Trem2 R47H alzheimer's risk variant impairs
- splicing and reduces Trem2 mRNA and protein in mice but not in humans. *Mol*
- 545 *Neurodegener*. 2018;13(1):49-6. doi: 10.1186/s13024-018-0280-6.
- 546 26. Sharifi R, Morra R, Appel CD, et al. Deficiency of terminal ADP-ribose protein
- 547 glycohydrolase TARG1/C6orf130 in neurodegenerative disease. EMBO J. 2013;32(9):1225-
- 548 1237. doi: 10.1038/emboj.2013.51.
- 549 27. Yamanaka T, Miyazaki H, Oyama F, et al. Mutant huntingtin reduces HSP70 expression
- through the sequestration of NF-Y transcription factor. *EMBO J.* 2008;27(6):827-839. doi:
- 551 10.1038/emboj.2008.23.
- 552 28. Katsuno M, Adachi H, Minamiyama M, et al. Disrupted transforming growth factor-beta
- signaling in spinal and bulbar muscular atrophy. *J Neurosci*. 2010;30(16):5702-5712. doi:
- 554 10.1523/JNEUROSCI.0388-10.2010.

- 555 29. Washington AV, Gibot S, Acevedo I, et al. TREM-like transcript-1 protects against
- 556 inflammation-associated hemorrhage by facilitating platelet aggregation in mice and
- 557 humans. J Clin Invest. 2009;119(6):1489-1501. doi: 10.1172/JCl36175.
- 30. Li L, Yang Y, Yang G, et al. The role of JAZF1 on lipid metabolism and related genes in
- vitro. *Metabolism*. 2011;60(4):523-530. doi: 10.1016/j.metabol.2010.04.021.
- 560 31. Shen R, Zhao X, He L, et al. Upregulation of RIN3 induces endosomal dysfunction in
- 561 alzheimer's disease. Transl Neurodegener. 2020;9(1):26-1. doi: 10.1186/s40035-020-00206-
- 562 1.
- 563 32. Bhattacharyya R, Teves CAF, Long A, Hofert M, Tanzi RE. The neuronal-specific
- isoform of BIN1 regulates beta-secretase cleavage of APP and abeta generation in a RIN3-
- 565 dependent manner. Sci Rep. 2022;12(1):3486-4. doi: 10.1038/s41598-022-07372-4.
- 33. Chapuis J, Flaig A, Grenier-Boley B, et al. Genome-wide, high-content siRNA screening
- 567 identifies the alzheimer's genetic risk factor FERMT2 as a major modulator of APP
- 568 metabolism. *Acta Neuropathol.* 2017;133(6):955-966. doi: 10.1007/s00401-016-1652-z.
- 34. Dowling JJ, Gibbs E, Russell M, et al. Kindlin-2 is an essential component of intercalated
- 570 discs and is required for vertebrate cardiac structure and function. *Circ Res.*
- 571 2008;102(4):423-431. doi: 10.1161/CIRCRESAHA.107.161489.
- 572 35. Shen Z, Ye Y, Dong L, et al. Kindlin-2: A novel adhesion protein related to tumor
- 573 invasion, lymph node metastasis, and patient outcome in gastric cancer. *Am J Surg*.
- 574 2012;203(2):222-229. doi: 10.1016/j.amjsurg.2011.06.050.
- 575 36. Sossey-Alaoui K, Pluskota E, Szpak D, Plow EF. The Kindlin2-p53-SerpinB2 signaling
- 576 axis is required for cellular senescence in breast cancer. *Cell Death Dis.* 2019;10(8):539-z.
- 577 doi: 10.1038/s41419-019-1774-z.
- 578 37. Larsson M, Duffy DL, Zhu G, et al. GWAS findings for human iris patterns: Associations
- 579 with variants in genes that influence normal neuronal pattern development. Am J Hum
- 580 *Genet.* 2011;89(2):334-343. doi: 10.1016/j.ajhg.2011.07.011.

- 581 38. Parry DA, Poulter JA, Logan CV, et al. Identification of mutations in SLC24A4, encoding
- 582 a potassium-dependent sodium/calcium exchanger, as a cause of amelogenesis imperfecta.
- 583 *Am J Hum Genet*. 2013;92(2):307-312. doi: 10.1016/j.ajhg.2013.01.003.
- 584 39. Khan SA, Khan MA, Muhammad N, et al. A novel nonsense variant in SLC24A4 causing
- 585 a rare form of amelogenesis imperfecta in a pakistani family. *BMC Med Genet*.
- 586 2020;21(1):97-6. doi: 10.1186/s12881-020-01038-6.
- 587 40. Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new
- 588 loci and functional pathways influencing alzheimer's disease risk. *Nat Genet*.
- 589 2019;51(3):404-413. doi: 10.1038/s41588-018-0311-9.
- 590 41. Marioni RE, Harris SE, Zhang Q, et al. GWAS on family history of alzheimer's disease.
- 591 *Transl Psychiatry*. 2018;8(1):99-6. doi: 10.1038/s41398-018-0150-6.
- 42. He Z, Liu L, Wang C, et al. Identification of putative causal loci in whole-genome
- 593 sequencing data via knockoff statistics. *Nat Commun.* 2021;12(1):3152-4. doi:
- 594 10.1038/s41467-021-22889-4.
- 43. Chen F, Chen H, Jia Y, Lu H, Tan Q, Zhou X. miR-149-5p inhibition reduces alzheimer's
- 596 disease beta-amyloid generation in 293/APPsw cells by upregulating H4K16ac via KAT8.
- 597 *Exp Ther Med.* 2020;20(5):88. doi: 10.3892/etm.2020.9216.
- 598 44. Li L, Ghorbani M, Weisz-Hubshman M, et al. Lysine acetyltransferase 8 is involved in
- 599 cerebral development and syndromic intellectual disability. J Clin Invest. 2020;130(3):1431-
- 600 1445. doi: 10.1172/JCI131145.
- 45. Dumitriu A, Golji J, Labadorf AT, et al. Integrative analyses of proteomics and RNA
- transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci
- 603 in parkinson disease. *BMC Med Genomics*. 2016;9:5-y. doi: 10.1186/s12920-016-0164-y.
- 46. Wainberg M, Andrews SJ, Tripathy SJ. Shared genetic risk loci between alzheimer's
- disease and related dementias, parkinson's disease, and amyotrophic lateral sclerosis.
- 606 Alzheimers Res Ther. 2023;15(1):113-3. doi: 10.1186/s13195-023-01244-3.
- 607
- 608

#### 609 Acknowledgments

- 610 We thank the contributors who collected samples used in this study, as well as patients and
- 611 their families, whose help and participation made this work possible.
- 612 <u>ADSP</u>: Data for this study were prepared, archived, and distributed by the National Institute
- on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania
- 614 (U24-AG041689), funded by the National Institute on Aging (accession NG00067). The full
- 615 acknowledgement statement for the ADSP can be found at:
- 616 https://dss.niagads.org/datasets/ng00067/
- ADNI: Data used in preparation of this article were obtained through NIAGADS. The investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:
- http://adni.loni.usc.edu/wp-content/uploads/how\_to\_apply/ADNI\_Acknowledgement\_List.pdf

## 623 Sources of Funding

- This work was funded through U01 AG058589 and U01 AG068221 from the National Instituteon Aging.
- 626 <u>ADSP</u>: All relevant funding is listed in the full acknowledgement statement for the ADSP that 627 can be found at: https://dss.niagads.org/datasets/ng00067/

ADNI: Data collection and sharing for ADNI was funded by the Alzheimer's Disease 628 Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD 629 630 ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the 631 National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, 632 and through generous contributions from the following: AbbVie, Alzheimer's Association; 633 Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-634 Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company 635 Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy 636

Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Disclosures The authors do not have declarations of interest to report. The funding sources of this study had no role in the study design, the collection, the analysis or the interpretation of data, in the writing of the report, or in the decision to submit the article for publication. 

## 665 Figure captions

- 666 Figure 1. Schematic of the ADSP 5K analysis
- 667 **Figure 2.** Top variants identified from single variant association analysis in the pooled sample
- 668 within 100kb of the 83 lead GWAS variants
- Variant ID is in the form of chromosome:position (effect allele). Positions provided are on build
- 670 38. EAF is the effect allele frequency, Meta-RE is the multi-population meta-analysis using a
- 671 random effect model, Meta-FE is the multi-population meta-analysis using a fixed effect model.
- The p-value for Meta-RE is calculated using Han and Eskin's random effects model. The effect
- size and its 95% CI is not shown for variants with a minor allele count (MAC) < 10 in population
- 674 specific analysis.
- 675





Figure 1. Schematic of ADSP 5K analysis

Color should be used.



**Figure 2.** Top variants identified from single variant association analysis in the pooled sample within 100kb of the 83 lead GWAS variants <u>Color should be used.</u>

|                    | All (N=4,567)  | AA* (N=995)  | HI* (N=1,516)  | EA* (N=2,043)   | Other (N=13)  |
|--------------------|--|--|--|---|---|
|                    | 76.9 (8.3)   | 79.2 (7.6)   | 75.1 (8.5)   | 77.1 (8.4)  | 77.3 (6.6)  |
|                    |  |  |  |   |   |
| Case               | 2184 (47.8%)   | 463 (46.5%)  | 795 (52.4%)  | 921 (45.1%)   | 5 (46.2%)   |
| Control            | 2383 (52.2%)   | 532 (53.5%)  | 721(47.6%)   | 1122 (54.9%)  | 8 (53.8%)   |
|                    |  |  |  |   |   |
| Female             | 2822 (61.8%)   | 710 (71.4%)  | 1020 (67.3%)   | 1086 (53.2%)  | 6 (38.5%)   |
| Male               | 1745 (38.2%)   | 285 (28.6%)  | 496 (32.7%)  | 957 (46.8%)   | 7 (61.5%)   |
|                    |  |  |  |   |   |
| ADNI               | 797 (17.5%)  | 26 (2.6%)  | 10 (0.7%)  | 750 (36.7%)   | 11 (84.6%)  |
| ADSP- case control | 2963 (64.9%)   | 944 (94.9%)  | 1107 (73.0%)   | 911 (44.6%)   | 1 (7.7%)  |
| ADSP- family       | 807 (17.7%)  | 25 (2.5%)  | 399 (26.3%)  | 382 (18.7%)   | 1 (7.7%)  |
|                    |  |  |  |   |   |
| Baylor             | 1241 (27.2%)   | 0 (0)  | 1103 (72.8%)   | 138 (6.8%)  | 0 (0)   |
| Broad              | 1263 (27.7%)   | 2 (0.2%)   | 286 (18.9%)  | 974 (47.7%)   | 1 (7.7%)  |
| Illumina           | 797 (17.5%)  | 26 (2.6%)  | 10 (0.7%)  | 750 (36.7%)   | 11 (84.6%)  |
|                    | Control<br>Female<br>Male<br>ADNI<br>ADSP- case control<br>ADSP- family<br>Baylor<br>Broad | 76.9 (8.3)         Case       2184 (47.8%)         Control       2383 (52.2%)         Female       2822 (61.8%)         Male       1745 (38.2%)         ADNI       797 (17.5%)         ADSP- case control       2963 (64.9%)         ADSP- family       807 (17.7%)         Baylor       1241 (27.2%)         Broad       1263 (27.7%) | 76.9 (8.3)       79.2 (7.6)         Case       2184 (47.8%)       463 (46.5%)         Control       2383 (52.2%)       532 (53.5%)         Female       2822 (61.8%)       710 (71.4%)         Male       1745 (38.2%)       285 (28.6%)         ADNI       797 (17.5%)       26 (2.6%)         ADSP- case control       2963 (64.9%)       944 (94.9%)         ADSP- family       807 (17.7%)       25 (2.5%)         Baylor       1241 (27.2%)       0 (0)         Broad       1263 (27.7%)       2 (0.2%) | 76.9 (8.3)       79.2 (7.6)       75.1 (8.5)         Case       2184 (47.8%)       463 (46.5%)       795 (52.4%)         Control       2383 (52.2%)       532 (53.5%)       721(47.6%)         Female       2822 (61.8%)       710 (71.4%)       1020 (67.3%)         Male       1745 (38.2%)       285 (28.6%)       496 (32.7%)         ADNI       797 (17.5%)       26 (2.6%)       10 (0.7%)         ADSP- case control       2963 (64.9%)       944 (94.9%)       1107 (73.0%)         ADSP- family       807 (17.7%)       25 (2.5%)       399 (26.3%)         Baylor       1241 (27.2%)       0 (0)       1103 (72.8%) | The second se |

# Table 1. Characteristics of the participants included in the ADSP R1 data set

|              |                | All (N=4,567) | AA* (N=995) | HI* (N=1,516) | EA* (N=2,043) | Other (N=13) |
|--------------|----------------|---------------|-------------|---------------|---------------|--------------|
|              | WashU          | 1266 (27.7%)  | 967 (97.2%) | 117 (7.7%)    | 181 (8.9%)    | 1 (7.7%)     |
| Platform (%) |                |               |             |               |               |              |
|              | HiSeq X Ten    | 3227 (70.7%)  | 965 (97.0%) | 1186 (78.2%)  | 1074 (52.6%)  | 2 (15.4%)    |
|              | HiSeq2000/2500 | 1340 (29.3%)  | 30 (3.0%)   | 330 (21.8%)   | 969 (47.4%)   | 11 (84.6%)   |

\*AA: Black/African-American, HI: Hispanic/Latino; EA: White/European ancestry. Populations defined are described in the Methods.

|                 |             |   |            |                             |                  | Pooled | I Single V | /ariant  | Condit  | ional  |
|-----------------|-------------|---|------------|-----------------------------|------------------|--------|------------|----------|---------|--------|
|                 |             |   |            |                             |                  | Assoc  | iation An  | Analysis |         |        |
| Chr:Pos:A2:A1*  | rsid        | Gene                                      | Location   | GWAS variants†              | GWAS loci†       | MAF    | Pvalue     | Beta     | Pvalue  | Beta   |
| 6:41067923:C:T  | rs115774857 | OARD1 (close<br>intronic<br>gene APOBEC2) |            | rs143332484,<br>rs75932628, | TREM2,<br>UNC5CL | 0.0080 | 1.0E-04    | 1.016    | 6.6E-05 | 1.047  |
| 6:41077355:A:G  | rs145520578 |   | intronic   | rs10947943                  | 0110002          | 0.0080 | 9.9E-05    | 1.018    | 6.4E-05 | 1.049  |
| 6:41077511:A:C  | rs115202236 | -   | intronic   | 1310947943                  |                  | 0.0081 | 9.9E-05    | 1.018    | 6.4E-05 | 1.049  |
| 6:41082030:G:A  | rs12200736  | OARD1, NFYA                               | intronic   | rs143332484,                | TREM2,           | 0.0080 | 1.0E-04    | 1.018    | 6.5E-05 | 1.048  |
| 6:41083056:C:T  | rs10947945  | OARDT, NETA                               | intronic   | rs75932628,                 | TREML2,          | 0.0080 | 1.0E-04    | 1.018    | 6.4E-05 | 1.049  |
| 6:41088533:T:C  | rs12210716  |   | intronic   | rs60755019,<br>rs10947943   | UNC5CL           | 0.0080 | 1.0E-04    | 1.018    | 6.4E-05 | 1.049  |
| 6:41147490:T:G  | rs12199328  | intergenic (close<br>gene TREML1)         |            | rs143332484,<br>rs75932628, | TREM2,           | 0.0080 | 1.0E-04    | 1.018    | 6.5E-05 | 1.048  |
| 6:41173956:G:A‡ | rs10947950‡ | intergenic                                | intergenic | rs60755019                  | TREML2           | 0.0128 | 1.4E-04    | 0.783    | 9.1E-05 | 0.806  |
| 7:28034934:T:A  | rs73683942  | JAZF1                                     | intronic   | rs1160871                   | JAZF1            | 0.0188 | 7.5E-05    | -0.627   | 3.3E-03 | -0.624 |

 Table 2. Significant variants from single variant association analysis in the pooled ADSP sample within 100kb of the 83 lead GWAS variants

|                    |              |                            |   |                          | Pooled     | d Single \ | /ariant   | Conditional<br>Analysis |         |        |
|--------------------|--------------|----------------------------|---|--------------------------|------------|------------|-----------|-------------------------|---------|--------|
|                    |              |                            |   |                          |            | Assoc      | iation An |                         |         |        |
| Chr:Pos:A2:A1*     | rsid         | Gene                       | Location  | GWAS variants†           | GWAS loci† | MAF Pvalue |           | Beta                    | Pvalue  | Beta   |
| 7:28034935:C:G     | rs78789160   |                            | intronic  |                          |            | 0.0188     | 7.5E-05   | -0.627                  | 3.3E-03 | -0.624 |
| 7:28035459:GAGAT:G | no rsids     |                            | intronic  |                          |            | 0.0188     | 1.9E-05   | -0.677                  | 3.9E-03 | -0.674 |
| 7:28037452:A:C     | rs73683943   |                            | intronic  |                          |            | 0.0191     | 3.8E-05   | -0.644                  | 3.6E-03 | -0.641 |
| 7:28042506:C:G     | rs60825597   |                            | intronic  |                          |            | 0.0196     | 7.8E-05   | -0.607                  | 3.3E-03 | -0.6   |
| 14:52885670:T:TA   | rs1310103853 | FERMT2                     | intronic  |                          | FERMT2     | 0.0174     | 4.5E-06   | 0.806                   | 3.8E-06 | 0.817  |
| 14:52932032:A:G    | rs60609189   |                            | intronic  | rs17125924               |            | 0.0189     | 7.4E-06   | 0.768                   | 8.4E-06 | 0.767  |
| 14:52992239:A:G    | rs12431954   | intergenic                 |   |                          |            | 0.0205     | 3.8E-06   | 0.763                   | 5.6E-06 | 0.752  |
| 14:92467728:C:T    | rs7155002    | SLC24A4                    | intronic  | rs12590654,<br>rs7401792 | SLC24A4    | 0.4460     | 1.4E-05   | -0.198                  | 4.6E-03 | -0.26  |
| 16:31117787:C:G    | rs201871085  | KAT8 (close<br>gene BCKDK) | missense<br>variant, non<br>coding transcript<br>exon variant | rs889555                 | BCKDK      | 0.0108     | 2.4E-05   | 0.926                   | 2.9E-05 | 0.916  |

\*A1 corresponds to the alternate (effect) allele; positions provided are on build 38

<sup>†</sup> The GWAS variants and GWAS loci are based on the GWAS list from Bellenguez et al (PMID: 35379992)

‡ Variant identified as significant in the multi-population meta-analysis (not in the pooled analysis)

MAF: Minor Allele Frequency

|                  | White / European Ancestry |        |      |          |        |     | Black / | Africa | an Americ | an     | Hispanic / Latino |       |      |          |        |  |
|------------------|---------------------------|--------|------|----------|--------|-----|---------|--------|-----------|--------|-------------------|-------|------|----------|--------|--|
| Chr:Pos:A2:A1*   | N                         | Freq   | MAC  | Pvalue   | Beta   | Ν   | Freq    | MAC    | Pvalue    | Beta   | N                 | Freq  | MAC  | Pvalue   | Beta   |  |
| 4:11052797:T:C   | 2040                      | 0.0002 | 1    | 3.04E-01 | 2.069  | 984 | 0.137   | 270    | 8.37E-05  | -0.534 | 1513              | 0.059 | 180  | 4.94E-01 | 0.113  |  |
| 4:11053332:C:T   | 2043                      | 0.0002 | 1    | 3.04E-01 | 2.068  | 995 | 0.137   | 273    | 8.66E-05  | -0.530 | 1516              | 0.059 | 179  | 4.83E-01 | 0.116  |  |
| 5:180211637:C:T  | 2042                      | 0.143  | 584  | 7.14E-05 | 0.385  | 995 | 0.052   | 104    | 8.00E-02  | -0.351 | 1514              | 0.110 | 333  | 9.48E-01 | 0.009  |  |
| 5:180214978:G:A  | 2042                      | 0.143  | 586  | 5.37E-05 | 0.392  | 994 | 0.051   | 101    | 1.45E-01  | -0.296 | 1514              | 0.109 | 330  | 9.39E-01 | 0.010  |  |
| 5:180216117:C:T  | 2041                      | 0.143  | 582  | 3.69E-05 | 0.400  | 995 | 0.050   | 100    | 1.72E-01  | -0.278 | 1512              | 0.096 | 289  | 6.05E-01 | 0.073  |  |
| 5:180222862:G:A  | 2042                      | 0.144  | 590  | 3.70E-05 | 0.398  | 995 | 0.079   | 157    | 3.94E-01  | -0.144 | 1516              | 0.124 | 377  | 9.75E-01 | 0.004  |  |
| 5:180224704:C:T  | 2041                      | 0.145  | 591  | 2.85E-05 | 0.403  | 989 | 0.081   | 160    | 3.81E-01  | -0.147 | 1511              | 0.124 | 375  | 9.48E-01 | -0.008 |  |
| 8:11868930:C:G   | 2043                      | 0.007  | 27   | 6.52E-05 | 1.627  | 995 | 0.003   | 6      | 5.52E-01  | -0.494 | 1516              | 0.009 | 26   | 3.26E-01 | -0.414 |  |
| 11:86068255:T:G  | 2042                      | 0.810  | 774  | 6.19E-01 | 0.044  | 992 | 0.886   | 226    | 5.53E-05  | 0.576  | 1516              | 0.811 | 572  | 8.58E-01 | -0.019 |  |
| 11:86068268:A:G  | 2042                      | 0.810  | 774  | 6.19E-01 | 0.044  | 990 | 0.887   | 224    | 2.49E-05  | 0.607  | 1515              | 0.811 | 572  | 8.45E-01 | -0.021 |  |
| 11:86072833:A:G  | 2042                      | 0.815  | 755  | 6.67E-01 | 0.038  | 992 | 0.888   | 222    | 5.37E-05  | 0.577  | 1516              | 0.816 | 559  | 7.35E-01 | -0.037 |  |
| 11:86186529:G:A  | 2038                      | 0.142  | 577  | 8.10E-02 | 0.169  | 993 | 0.264   | 525    | 1.21E-04  | -0.403 | 1516              | 0.245 | 742  | 1.52E-01 | 0.137  |  |
| 14:105740487:C:T | 1863                      | 0.524  | 1772 | 2.12E-05 | -0.479 | 981 | 0.308   | 605    | 5.33E-01  | 0.074  | 1446              | 0.430 | 1244 | 7.48E-02 | 0.204  |  |
| 15:63375962:G:A  | 2042                      | 0.0002 | 1    | 2.53E-01 | 2.318  | 994 | 0.101   | 200    | 1.18E-04  | 0.591  | 1514              | 0.035 | 105  | 9.71E-01 | 0.008  |  |

Table 3. Significant variants from single variant association analysis in the population subsamples within 100kb of the 83 lead GWAS variants

|                 | White / European Ancestry |        |     |          |        |     | Black | Africa | an Americ | an     | Hispanic / Latino |       |     |          |        |  |
|-----------------|---------------------------|--------|-----|----------|--------|-----|-------|--------|-----------|--------|-------------------|-------|-----|----------|--------|--|
| Chr:Pos:A2:A1*  | N                         | Freq   | MAC | Pvalue   | Beta   | N   | Freq  | MAC    | Pvalue    | Beta   | Ν                 | Freq  | MAC | Pvalue   | Beta   |  |
| 15:63376200:A:G | 2042                      | 0.0002 | 1   | 2.53E-01 | 2.317  | 994 | 0.106 | 210    | 1.24E-04  | 0.576  | 1515              | 0.040 | 122 | 7.96E-01 | -0.052 |  |
| 16:31117787:C:G | 1917                      | 0.020  | 76  | 1.11E-04 | 0.961  | 991 | 0.004 | 7      | 1.77E-01  | 1.033  | 1489              | 0.004 | 12  | 5.16E-01 | 0.412  |  |
| 16:86357432:T:C | 2043                      | 0.088  | 359 | 3.53E-05 | -0.497 | 995 | 0.132 | 262    | 7.55E-01  | -0.043 | 1516              | 0.097 | 293 | 4.62E-01 | 0.100  |  |
| 17:46724128:T:C | 2043                      | 0.007  | 30  | 3.58E-05 | 1.607  | 995 | 0.002 | 3      | 5.80E-01  | -0.643 | 1515              | 0.006 | 17  | 3.75E-01 | 0.514  |  |
| 17:46747538:C:T | 2043                      | 0.007  | 28  | 3.69E-05 | 1.649  | 994 | 0.002 | 3      | 5.79E-01  | -0.645 | 1515              | 0.006 | 17  | 3.76E-01 | 0.513  |  |
| 17:58269710:G:A | 2042                      | 0.016  | 67  | 7.96E-05 | 1.069  | 995 | 0.004 | 8      | 7.23E-01  | 0.256  | 1515              | 0.005 | 14  | 7.84E-01 | -0.169 |  |
| 20:56407698:G:A | 2037                      | 0.004  | 16  | 3.43E-05 | 2.328  | 991 | 0.001 | 2      | 8.15E-01  | 0.339  | 1516              | 0.002 | 6   | 8.86E-01 | -0.172 |  |
| 20:56490678:G:T | 2041                      | 0.005  | 19  | 4.74E-05 | 2.021  | 995 | 0.002 | 4      | 4.93E-01  | -0.703 | 1516              | 0.002 | 6   | 8.86E-01 | -0.172 |  |
| 20:56505267:G:A | 2041                      | 0.005  | 20  | 1.57E-05 | 2.095  | 995 | 0.002 | 4      | 4.93E-01  | -0.703 | 1513              | 0.002 | 6   | 8.83E-01 | -0.177 |  |

\*A1 corresponds to the alternate (effect) allele; positions provided are on build 38

Variants with a minor allele count (MAC) < 10 in a population subsample were not included in the meta-analysis